{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:58:33Z","timestamp":1793951913165,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04398-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:02:05Z","timestamp":1779181325000},"page":"2073-2082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6463-6321","authenticated-orcid":false,"given":"Ivan","family":"Martinez-Valbuena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-5262","authenticated-orcid":false,"given":"Maziar","family":"Emamikhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Olszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrina K.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed-Mohammad","family":"Fereshtehnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai Gil D.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-6435","authenticated-orcid":false,"given":"Mario","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1356-4919","authenticated-orcid":false,"given":"Daniel G.","family":"Di Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-6456","authenticated-orcid":false,"given":"Janet","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Anastassiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sasitharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi P.","family":"Visanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8437-3645","authenticated-orcid":false,"given":"Brit","family":"Mollenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-8497","authenticated-orcid":false,"given":"M. Carmela","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor G.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-3667","authenticated-orcid":false,"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"4398_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ncl.2024.12.006","volume":"43","author":"N Olfati","year":"2025","unstructured":"Olfati, N., Akhoundi, F. H. & Litvan, I. Atypical Parkinsonian disorders. Neurol. Clin. 43, 249\u2013277 (2025).","journal-title":"Neurol. Clin."},{"key":"4398_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"4398_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning, G. K. et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov. Disord. 37, 1131\u20131148 (2022).","journal-title":"Mov. Disord."},{"key":"4398_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"4398_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","volume":"72","author":"GG Kovacs","year":"2019","unstructured":"Kovacs, G. G. Molecular pathology of neurodegenerative diseases: principles and practice. J. Clin. Pathol. 72, 725\u2013735 (2019).","journal-title":"J. Clin. Pathol."},{"key":"4398_CR6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1212\/WNL.46.4.922","volume":"46","author":"I Litvan","year":"1996","unstructured":"Litvan, I. et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele\u2013Richardson\u2013Olszewski syndrome). Neurology 46, 922\u2013930 (1996).","journal-title":"Neurology"},{"key":"4398_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"4398_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01206-6","volume":"11","author":"SH Fox","year":"2025","unstructured":"Fox, S. H. et al. Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases. NPJ Parkinsons Dis. 11, 360 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"4398_CR9","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","volume":"186","author":"AL Boxer","year":"2023","unstructured":"Boxer, A. L. & Sperling, R. Accelerating Alzheimer\u2019s therapeutic development: the past and future of clinical trials. Cell 186, 4757\u20134772 (2023).","journal-title":"Cell"},{"key":"4398_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00702-024-02797-9","volume":"131","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. & Lang, A. E. The why and how of the SynNerGe criteria of Parkinson\u00b4s disease. J. Neural Transm. 131, 1149\u20131154 (2024).","journal-title":"J. Neural Transm."},{"key":"4398_CR11","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"4398_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"4398_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"4398_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"4398_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214648","volume":"106","author":"DG Coughlin","year":"2026","unstructured":"Coughlin, D. G. et al. CSF \u03b1-synuclein seed amplification assays and skin immunofluorescence: clinical applications, research opportunities, and knowledge gaps. Neurology 106, e214648 (2026).","journal-title":"Neurology"},{"key":"4398_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12978-5","volume":"272","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Skin \u03b1-synuclein assays in diagnosing Parkinson\u2019s disease: a systematic review and meta-analysis. J. Neurol. 272, 326 (2025).","journal-title":"J. Neurol."},{"key":"4398_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209818","volume":"103","author":"C Anastassiadis","year":"2024","unstructured":"Anastassiadis, C. et al. CSF \u03b1-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology 103, e209818 (2024).","journal-title":"Neurology"},{"key":"4398_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","volume":"24","author":"CD Orr\u00fa","year":"2025","unstructured":"Orr\u00fa, C. D. et al. Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: a longitudinal cohort study. Lancet Neurol. 24, 580\u2013590 (2025).","journal-title":"Lancet Neurol."},{"key":"4398_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214406","volume":"106","author":"CH Li","year":"2026","unstructured":"Li, C. H. et al. Plasma pTau217 and neurofilament light chain as differentiative markers for progressive supranuclear palsy from Parkinson disease. Neurology 106, e214406 (2026).","journal-title":"Neurology"},{"key":"4398_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1638852","volume":"16","author":"G Musso","year":"2025","unstructured":"Musso, G. et al. Detecting amyloid and tau pathology in Parkinson\u2019s disease, 4R-tauopathies and control subjects with plasma pTau217. Front. Neurol. 16, 1638852 (2025).","journal-title":"Front. Neurol."},{"key":"4398_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ana.26930","volume":"96","author":"I Garcia-Cordero","year":"2024","unstructured":"Garcia-Cordero, I. et al. Evaluating the effect of Alzheimer\u2019s disease-related biomarker change in corticobasal syndrome and progressive supranuclear palsy. Ann. Neurol. 96, 99\u2013109 (2024).","journal-title":"Ann. Neurol."},{"key":"4398_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105925","volume":"120","author":"I Martinez-Valbuena","year":"2025","unstructured":"Martinez-Valbuena, I., Fullam, S., O\u2019Dowd, S., Tartaglia, M. C. & Kovacs, G. G. \u03b1-Synuclein seed amplification assay positivity beyond synucleinopathies. EBioMedicine 120, 105925 (2025).","journal-title":"EBioMedicine"},{"key":"4398_CR23","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1001\/jamaneurol.2025.1630","volume":"82","author":"I Martinez-Valbuena","year":"2025","unstructured":"Martinez-Valbuena, I., Tartaglia, M. C., Kovacs, G. G. & Lang, A. E. Copathology in atypical Parkinsonism\u2014the rule rather than the exception? JAMA Neurol. 82, 1083\u20131084 (2025).","journal-title":"JAMA Neurol."},{"key":"4398_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaneurol.2024.3162","volume":"81","author":"I Martinez-Valbuena","year":"2024","unstructured":"Martinez-Valbuena, I., Tartaglia, M. C., Fox, S. H., Lang, A. E. & Kovacs, G. G. Four-repeat tau seeding in the skin of patients with progressive supranuclear palsy. JAMA Neurol. 81, 1228\u20131230 (2024).","journal-title":"JAMA Neurol."},{"key":"4398_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00781-1","volume":"19","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Seeding activity of skin misfolded tau as a biomarker for tauopathies. Mol. Neurodegener. 19, 92 (2024).","journal-title":"Mol. Neurodegener."},{"key":"4398_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00728-9","volume":"10","author":"IL Dellarole","year":"2024","unstructured":"Dellarole, I. L. et al. Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies. NPJ Parkinsons Dis. 10, 116 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"4398_CR27","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/mdc3.70226","volume":"12","author":"DA Olszewska","year":"2025","unstructured":"Olszewska, D. A. & Lang, A. E. How do I do a skin punch biopsy for research and diagnostic purposes in Parkinson\u2019s disease and atypical parkinsonism? Mov. Disord. Clin. Pract. 12, 2032\u20132033 (2025).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"4398_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10067-014-2850-5","volume":"34","author":"TD Levine","year":"2015","unstructured":"Levine, T. D. & Saperstein, D. S. Routine use of punch biopsy to diagnose small fiber neuropathy in fibromyalgia patients. Clin. Rheumatol. 34, 413\u2013417 (2015).","journal-title":"Clin. Rheumatol."},{"key":"4398_CR29","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1212\/WNL.0000000000001335","volume":"84","author":"C Edwards","year":"2015","unstructured":"Edwards, C., Leira, E. C. & Gonzalez-Alegre, P. Residency training: a failed lumbar puncture is more about obesity than lack of ability. Neurology 84, e69\u2013e72 (2015).","journal-title":"Neurology"},{"key":"4398_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411624","volume":"24","author":"S Coppens","year":"2023","unstructured":"Coppens, S., Lehmann, S., Hopley, C. & Hirtz, C. Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int. J. Mol. Sci. 24, 11624 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"4398_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2015.03.041","volume":"352","author":"W Sako","year":"2015","unstructured":"Sako, W., Murakami, N., Izumi, Y. & Kaji, R. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson\u2019s disease from atypical parkinsonism: evidence from a meta-analysis. J. Neurol. Sci. 352, 84\u201387 (2015).","journal-title":"J. Neurol. Sci."},{"key":"4398_CR32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mds.28912","volume":"37","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena, I. et al. Combining skin \u03b1-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson\u2019s disease. Mov. Disord. 37, 648\u2013650 (2022).","journal-title":"Mov. Disord."},{"key":"4398_CR33","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas, J. C. et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90, e273\u2013e281 (2018).","journal-title":"Neurology"},{"key":"4398_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00768-1","volume":"10","author":"CC Pedersen","year":"2024","unstructured":"Pedersen, C. C. et al. Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson\u2019s disease. NPJ Parkinsons Dis. 10, 162 (2024).","journal-title":"NPJ Parkinsons Dis."},{"key":"4398_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213438","volume":"104","author":"E Sanchez","year":"2025","unstructured":"Sanchez, E. et al. Association of plasma biomarkers with longitudinal atrophy and microvascular burden on MRI across neurodegenerative and cerebrovascular diseases. Neurology 104, e213438 (2025).","journal-title":"Neurology"},{"key":"4398_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70248","volume":"21","author":"T Popli","year":"2025","unstructured":"Popli, T. et al. High rates of diagnostic discordance and co-pathology: insights into PSP from the NACC dataset. Alzheimers Dement. 21, e70248 (2025).","journal-title":"Alzheimers Dement."},{"key":"4398_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41467-025-67744-y","volume":"17","author":"I Martinez-Valbuena","year":"2025","unstructured":"Martinez-Valbuena, I. et al. 4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy. Nat. Commun. 17, 1006 (2025).","journal-title":"Nat. Commun."},{"key":"4398_CR38","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/jnen\/nlad025","volume":"82","author":"ED Driver-Dunckley","year":"2023","unstructured":"Driver-Dunckley, E. D. et al. Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 82, 438\u2013451 (2023).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"4398_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00401-013-1157-y","volume":"126","author":"GG Kovacs","year":"2013","unstructured":"Kovacs, G. G. et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 126, 365\u2013384 (2013).","journal-title":"Acta Neuropathol."},{"key":"4398_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","volume":"139","author":"E Saijo","year":"2020","unstructured":"Saijo, E. et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 139, 63\u201377 (2020).","journal-title":"Acta Neuropathol."},{"key":"4398_CR41","first-page":"1754","volume":"63","author":"K Messerschmidt","year":"2022","unstructured":"Messerschmidt, K. et al. 18F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy. J. Nucl. Med. 63, 1754\u20131760 (2022).","journal-title":"J. Nucl. Med."},{"key":"4398_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt, A. M. et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol. 149, 20 (2025).","journal-title":"Acta Neuropathol."},{"key":"4398_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02973-5","volume":"151","author":"M Gerasimenko","year":"2026","unstructured":"Gerasimenko, M. et al. Biochemical signatures of skin \u03b1-synuclein in synucleinopathies revealed by RT-QuIC assay end-product analysis. Acta Neuropathol. 151, 3 (2026).","journal-title":"Acta Neuropathol."},{"key":"4398_CR44","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1474-4422(24)00395-8","volume":"23","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol. 23, 1225\u20131237 (2024).","journal-title":"Lancet Neurol."},{"key":"4398_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2025.0112","volume":"82","author":"DE Vaillancourt","year":"2025","unstructured":"Vaillancourt, D. E. et al. Automated imaging differentiation for parkinsonism. JAMA Neurol. 82, 495\u2013505 (2025).","journal-title":"JAMA Neurol."},{"key":"4398_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48961-3","volume":"15","author":"J H\u00e4llqvist","year":"2024","unstructured":"H\u00e4llqvist, J. et al. Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset. Nat. Commun. 15, 4759 (2024).","journal-title":"Nat. Commun."},{"key":"4398_CR47","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.30028","volume":"39","author":"GG Kovacs","year":"2024","unstructured":"Kovacs, G. G. et al. Biomarker-based approach to \u03b1-synucleinopathies: lessons from neuropathology. Mov. Disord. 39, 2173\u20132179 (2024).","journal-title":"Mov. Disord."},{"key":"4398_CR48","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund, L. O. et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32, 1318\u20131322 (2001).","journal-title":"Stroke"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04398-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:03:26Z","timestamp":1781791406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04398-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4398"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04398-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M.-V., G.G.K. and A.E.L. share a pending patent for diagnostic assays for movement disorders (18\/537,455). G.G.K. has a shared patent for the 5G4 synuclein antibody. Outside the submitted work, I.M.-V. receives funding from the Michael J. Fox Foundation for Parkinson Research and consultancy fees from Ferrer. D.A.O. receives research funding from the Michael J. Fox Foundation for Parkinson Research. N.G.D.R. is a recipient of the Brain and Behavior Research Foundation Young Investigator Award and Ontario Graduate Scholarship. M.S. has received fellowship funding from the Dystonia Medical Research Foundation of Canada and is supported by grants from the Swiss National Science Foundation, Parkinson Schweiz and the Gottfried und Julia Bangerter-Rhyner Foundation. He has also received financial support from Boston Scientific, Medtronic, Zambon and Bial. S.H.F. receives research Funding from the Michael J. Fox Foundation for Parkinson Research, the NIH (Dystonia Coalition), Parkinson Canada and the Weston Foundation; honoraria from the International Parkinson and Movement Disorder Society; consultancy\/speaker fees from Abbvie, Lundbeck and Sunovion; and Royalties from Oxford University Press. B.M. has received honoraria for consultancy or educational presentations from GE Healthcare, Bial, Roche, Biogen, AbbVie, Desitin and Amprion. B.M. is a member of the executive steering committee of the Parkinson Progression Marker Initiative of the Michael J. Fox Foundation for Parkinson\u2019s Research and has received research funding from Aligning Science Across Parkinson\u2019s disease (Aligning Sciences Across Parkinson\u2019s, Collaborative Research Network). M.C.T. receives funding from the NIH, the Weston Brain Foundation, the Tanenbaum Institute for Research in Science of Sport, the Canadian Institutes of Health Research and in-kind funding from Roche; she has served as an advisor to Eisai, Lilly and Novo Nordisk, and she conducts clinical trials for Biogen, Anavex, Janssen, Novo Nordisk, Bristol Myers Squibb, Aribio, Green Valley, UCB and Passage Bio. G.G.K. reports personal fees from Parexel, Mitsubishi-Tanabe, Ferrer and Treventis, and other funding from the MSA Coalition, the Michael J. Fox Foundation, Parkinson Canada, the NIH, the Canada Foundation for Innovation and the Ontario Research Fund; in addition, G.G.K. received royalties from Wiley, Univ. of Cambridge, Taylor & Francis and Elsevier. A.E.L. has served as an advisor for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, Bristol Myers Squibb, Denali, EG427, Ferrer, Janssen, Lilly, Northera, Pharma 2B, Sun Pharma, UCB and Ventyx Bio; received honoraria from Sun Pharma and AbbVie; received grants from Brain Canada, the Canadian Institutes of Health Research, the Michael J. Fox Foundation, the Parkinson Foundation, Parkinson Canada and the Weston Foundation. A.E.L. is serving as an expert witness in litigation related to paraquat and PD, and has received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press and Cambridge Univ. Press. M.E., S.K.W., S.S., S.-M.F., D.G.D.L., J.T., C.A., J.L., P.B., J.S. and N.P.V. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}